Renovaro Yönetim

Yönetim kriter kontrolleri 1/4

Renovaro CEO'su David Weinstein, Oct2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.16% doğrudan sahiptir ve bu hisselerin değeri $ 154.93K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 3.3 yıldır.

Anahtar bilgiler

David Weinstein

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Enochian stock climbs on US patent for oncology platform

Oct 17

Enochian BioSciences discovers two sets of altered animal data in two of its studies

Jul 01

Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment

Jun 14

Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?

Feb 14

CEO

David Weinstein (64 yo)

less than a year

Görev süresi

Mr. David H. Weinstein, also known as David, is CEO & Director of Renovaro Inc. from October 14, 2024. Mr. Weinstein has extensive experience with U.S. securities and investment banking firms. He has been...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Simon Tarsh	Interim Chief Financial Officer	less than a year	US$330.33k	Veri yok
Francois Binette	COO and Executive VP for Research & Development	2yrs	US$430.29k	0% $ 0
David Weinstein	CEO & Director	less than a year	Veri yok	0.16% $ 154.9k
Serhat Gümrükcü	Co-Founder & Inventor	no data	Veri yok	11.3% $ 10.9m
Greg Duczynski	Senior Vice President for Clinical Operations	2.6yrs	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim: RENB 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Weinstein	CEO & Director	less than a year	Veri yok	0.16% $ 154.9k
James McNulty	Independent Director	less than a year	Veri yok	Veri yok
Richard Whitley	Member of Respiratory Diseases Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Anna Lok	Member of HBV Scientific Advisory Board	3.3yrs	Veri yok	Veri yok
Carol Brosgart	Chairperson of HBV Cure Scientific Advisory Board	4.3yrs	US$129.74k	0% $ 0
Fabien Zoulim	Member of HBV Scientific Advisory Board	4.3yrs	Veri yok	Veri yok
Maurice Van Tilburg	Independent Director	less than a year	Veri yok	Veri yok
Mark Collins	Independent Director	less than a year	Veri yok	Veri yok
W. Hardy	Chairman of HIV Scientific Advisory Board	6.3yrs	Veri yok	Veri yok
Steven Deeks	Member of HIV Scientific Advisory Board	6.8yrs	Veri yok	Veri yok
Peter Revill	Member of HBV Scientific Advisory Board	4.3yrs	Veri yok	Veri yok
Geert Kazemier	Chairman of Scientific Advisory Board	less than a year	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

72yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RENB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Renovaro Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Renovaro Inc. Announces CEO Changes

Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board

Renovaro Inc. Announces Board Changes

Renovaro Biosciences Inc. Appoints Avram Miller as Board of Directors

Renovaro Biosciences Inc. Appoints Leni Boeren and Ruud Hendriks as Independent Directors

Enochian Biosciences Inc., Annual General Meeting, Jun 22, 2023

Recent updates

Renovaro Inc. Announces CEO Changes

Renovaro Inc. announced delayed annual 10-K filing

Renovaro Receives Deficiency Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board

Renovaro Inc. Announces Board Changes

Renovaro Biosciences Inc. (NasdaqCM:RENB) completed the acquisition of GEDi Cube Intl Ltd.

Renovaro Biosciences Inc. Appoints Avram Miller as Board of Directors

Renovaro Biosciences Inc. Appoints Leni Boeren and Ruud Hendriks as Independent Directors

Renovaro Biosciences Inc. announced delayed annual 10-K filing

Renovaro Biosciences Inc. (NasdaqCM:RENB) signed a letter-of-intent to acquire GEDi Cube Intl Ltd.

Enochian Biosciences Inc. Receives Non-Compliance Letter from Nasdaq

New major risk - Share price stability

Enochian Biosciences Inc.(NasdaqCM:ENOB) dropped from Russell Small Cap Comp Value Index

Enochian Biosciences Inc. Announces That Its Cancer Platform Remains on Track for Trials in Humans Following FDA Review

Enochian Biosciences Inc., Annual General Meeting, Jun 22, 2023

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for Period Ended September 30, 2022

Enochian Biosciences, Inc. announced delayed 10-Q filing

Enochian Biosciences Receives Notice from Nasdaq for Not Filing Form 10-K

Enochian stock climbs on US patent for oncology platform

Enochian Biosciences, Inc. announced delayed annual 10-K filing

Rosen Law Firm Encourages Enochian Biosciences Investors to Secure Counsel Before Important September 26 Deadline in Securities Class Action

Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Enochian Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Enochian Biosciences, Inc

Johnson Fistel, LLP Announces That A Class Action Lawsuit Commence on Behalf of Investors of Enochian Biosciences Inc

Enochian BioSciences discovers two sets of altered animal data in two of its studies

Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?

High number of new directors

Enochian BioSciences Appoints Dr. François Binette, Ph.D. as Executive Vice President for Research and Development

Enochian Biosciences, Inc. Announces Appointment of Greg Duczynski as Senior Vice President for Clinical Operations

High number of new directors

Enochian Biosciences, Inc. Announces Resignation of Carl Sandler as Member of the Board of Directors

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Enochian Biosciences, Inc., Annual General Meeting, Mar 14, 2022

Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?

Enochian Biosciences, Inc. Announces Its Successful Completion of FDA Pre-IND for A Potential Cure for Hepatitis B Virus Infection

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity

Enochian Biosciences, Inc.(NasdaqCM:ENOB) dropped from Russell 3000E Value Index

Enochian Biosciences: A Follow Through For An HIV Cure

Enochian BioSciences, Inc. Announces FDA Acceptance of Pre-IND Request for Potential HIV Cure

Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment

New 90-day high: US$4.51

Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?

Enochian Biosciences, Inc., Annual General Meeting, Mar 05, 2021

New 90-day high: US$3.51

New 90-day low: US$3.02

New 90-day low: US$3.17

New 90-day low: US$3.40

New 90-day low - US$3.59

Enochian Biosciences, Inc.(NasdaqCM:ENOB) dropped from Russell 3000 Growth Index

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş